Business Wire·Nov 11, 2026, 8:15 AM ET

Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo

Rallybio Corporation issued a correction to its November 10, 2026 press release regarding the effective time of its one-for-two reverse stock split.
The reverse stock split is now expected to become effective at 4:01 p.m. Eastern Time on November 20, 2026, instead of the previously stated 12:01 a.m.
Trading on a post-reverse stock split basis is expected to commence on November 23, 2026.
The split is part of the Agreement \& Plan of Merger \& Reorganization dated May 31, 2026, involving Rallybio, Avenzo Therapeutics, Inc., \& Farmington Merger Sub, Inc.
Avenzo Therapeutics is a clinical-stage biotechnology company developing oncology therapies including CDK2 \& CDK4 inhibitors (AVZO-021, AVZO-023) \& bispecific ADCs (AVZO-1418, AVZO-103).
Rallybio is a clinical-stage biotechnology company focused on therapies for severe \& rare diseases in complement dysregulation \& hematology.
The press release includes forward-looking statements regarding the merger \& stock split, subject to risks such as Nasdaq listing approval delays or termination of the merger agreement.
No offer or solicitation to sell securities is made in this document.